INTEREST: Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS) - Geoff Bellingan

Dr Bellingan is a consultant in Respiratory Medicine and Critical Care at University College London Hospitals NHS Foundation Trust. Dr Geoff Bellingan is Medical Director for the Surgery and Cancer Board at University College London Hospitals (UCLH) and is responsible for the cancer strategy across the trust and UCLH engagement with UCLP and London Cancer. He is also responsible for surgical, anaesthetic and theatre strategy for the UCH site and for the imaging department. Geoff is a consultant in intensive care medicine (UCLH) and Reader in Intensive Care at UCL. He is the Hon secretary of the European Society of Intensive Care Medicine (ESICM)  and is a member of the Critical Care Committee for the Royal College of Physicians and the research committee for the Intensive Care Society (ICS). Geoff's research interests are ARDS infection and the resolution of inflammation, having studied macrophage clearance then fibrosis in ARDS for his PhD and MRC clinician scientist fellowships respectively. Geoff has published widely on pathophysiology and clinical trials in acute lung injury and on MRSA. He is currently leading on the FP7 trial.